 | |
| Company type | Public |
|---|---|
| |
| Industry | Pharmaceutical |
| Founded | 2002 |
| Headquarters | Cambridge, Massachusetts, U.S. |
Key people | Yvonne Greenstreet (CEO) |
| Revenue |  US$1.83 billion (2023) US$1.04 billion (2022)[1] |
Number of employees | 2,100 (2023)[2] |
| Website | alnylam |
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics[3] for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.[4] In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.[5]
- ^ "Alnylam Pharmaceuticals Inc. Annual Income Statement". MarketWatch. 12 August 2023.
- ^ "Alnylam Pharmaceuticals: Number of Employees 2006-2021". www.macrotrends.net.
- ^ "Alnylam Pharmaceuticals Inc (ALNY) Quote - XNAS | Morningstar. Alnylam Pharmaceuticals Inc's Company Profile. Business Description". www.morningstar.com. Retrieved 15 May 2022.
- ^ "ALNY | Alnylam Pharmaceuticals Inc. Company Profile & Executives - WSJ". www.wsj.com. Retrieved 15 May 2022.
- ^ "Most Innovative Growth Companies #100 Alnylam Pharmaceuticals". Forbes. May 2016. Retrieved September 22, 2016.